目的 探討紅花注射液聯(lián)合注射用尿激酶治療急性心肌梗死的臨床療效。方法 選取2019年8月—2020年11月在信陽市中心醫(yī)院就診的84例急性心肌梗死患者，按照隨機數(shù)字表法將所有患者分為對照組和治療組，每組各42例。對照組靜脈滴注注射用尿激酶，10萬UI加入250 mL生理鹽水靜脈滴注，在90 min滴完。治療組在對照組基礎上靜脈滴注紅花注射液，20 mL加入到250 mL葡萄糖注射液中充分稀釋，1次/d。兩組患者連續(xù)治療14 d。觀察兩組的臨床療效，比較兩組患者治療前后心絞痛程度、心功能指標和血清炎性因子水平。結果 治療后，治療組的總有效率為95.24%，對照組的總有效率為80.95%，組間比較有顯著性差異（P<0.05）。治療后，兩組的VAS評分明顯降低（P<0.05），且治療組VAS評分明顯低于對照組（P<0.05）。治療后，兩組的左室射血分數(shù)（LVEF）、每搏輸出量（SV）明顯升高，左室收縮末容積（LVESV）明顯降低（P<0.05）；治療后，治療組的LVEF、SV高于對照組，LVESV低于對照組，差異有統(tǒng)計學意義（P<0.05）。治療后，兩組的腫瘤壞死因子-α（TNF-α）、白細胞介素-6（IL-6）、腦鈉肽（BNP）水平顯著降低（P<0.05）；治療組的TNF-α、IL-6、BNP水平低于對照組，差異有統(tǒng)計學意義（P<0.05）。結論 紅花注射液聯(lián)合注射用尿激酶可提高急性心肌梗死的療效，有助于改善心功能，減輕心絞痛程度和炎癥反應。

Objective To investigate the clinical efficacy of Honghua Injection combined with Urokinase for injection in treatment of acute myocardial infarction. Methods Patients (84 cases) with acute myocardial infarction in Xinyang Central Hospital from August 2019 to November 2020 were randomly divided into control and treatment groups, and each group had 42 cases. Patients in the control group were iv administered with Urokinase for injection, 100 thousand UI added into normal saline 250 mL, dripped at 90 min. Patients in the treatment group were iv administered with Honghua Injection on the basis of the control group, 20 mL added into glucose injection 250 mL, once daily. Patients were treated for 14 d. After treatment, the clinical efficacies were evaluated, and the degree of angina pectoris, the index of cardiac function, and the levels of serum inflammatory factors in two groups were compared. Results After treatment, the total effective rate of the treatment group was 95.24%, and that of the control group was 80.95%, with significant difference between the two groups (P<0.05). After treatment, the VAS score of two groups were significantly decreased (P<0.05), and the VAS score of the treatment group was significantly lower than that of the control group (P<0.05). After treatment, the LVEF and SV of two groups were significantly increased, but the LVESV was significantly decreased (P<0.05). After treatment, the LVEF and SV of the treatment group were higher than those of the control group, but the LVESV was lower than that of the control group, the difference was statistically significant (P<0.05). After treatment, the levels of TNF-α, IL-6, and BNP in two groups were significantly decreased (P<0.05). After treatment, the levels of TNF-α, IL-6, and BNP in the treatment group were lower than those in the control group (P<0.05). Conclusion Honghua Injection combined with Urokinase for injection can improve the efficacy of acute myocardial infarction, help to improve cardiac function, reduce the degree of angina pectoris and inflammatory reaction.

R972

河南省高等學校重點科研項目（19A320028）